Manuscript

Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry

Retrieved on: 
torsdag, april 18, 2024

“We are delighted that our research on phenethylamine serotonin 5-HT2 receptor agonists was published in this important journal,” said Doug Drysdale, Chief Executive Officer of Cybin.

Key Points: 
  • “We are delighted that our research on phenethylamine serotonin 5-HT2 receptor agonists was published in this important journal,” said Doug Drysdale, Chief Executive Officer of Cybin.
  • “This study is an example of our expanding scope of innovative development work beyond our clinical tryptamine programs.
  • This research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist with favorable PK and PD properties,” concluded Dr. Varty.
  • Title: Synthesis and Structure-Activity Relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of CYB210010: A potent, orally bioavailable and long-acting serotonin 5-HT2 receptor agonist

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Retrieved on: 
måndag, april 15, 2024

Biomedicines is a highly reputable journal that publishes articles on clinical and basic science topics in medicine.

Key Points: 
  • Biomedicines is a highly reputable journal that publishes articles on clinical and basic science topics in medicine.
  • Dr. Etzion is the Head, Department of Gastroenterology and Liver Diseases, at Soroka University Medical Center, Beer Sheva, Israel.
  • This dual activity enables the drug to have positive effects in both liver cancer and MASH.
  • The drug mechanism of action which is presented in the manuscript and entails inflammatory cytokine inhibition together with the stimulation of positive cytokines, position Namodenoson as a promising safe drug,” stated Dr. Etzion.

Society for Immunotherapy of Cancer Publishes Recommendations on Optimal Intratumoral Immunotherapy Clinical Trial (IICT) Design

Retrieved on: 
tisdag, april 23, 2024

MILWAUKEE, April 23, 2024 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a new manuscript "Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease" in the Journal for ImmunoTherapy of Cancer.

Key Points: 
  • The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a new manuscript "Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease" in the Journal for ImmunoTherapy of Cancer.
  • MILWAUKEE, April 23, 2024 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a new manuscript " Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease " in the Journal for ImmunoTherapy of Cancer.
  • "With the recommendations provided in the manuscript, researchers can optimize clinical trial design and the delivery of intratumoral immunotherapies."
  • said Jason Luke, MD, FACP, chair of the SITC Intratumoral Immunotherapy Clinical Trials Manuscript Development Group.

Qunnect Achieves Record-Breaking Performance for Distributing Polarization Qubits on GothamQ Network in NYC

Retrieved on: 
måndag, april 15, 2024

BROOKLYN, N.Y., April 15, 2024 /PRNewswire/ -- Qunnect, a leader in quantum-secure networking technology, today announced that GothamQ, its quantum network utilizing existing commercial fiber optic cable, surpassed previous performance metrics in enabling the distribution of polarization-based quantum entanglement while delivering exceptionally high rates of preservation and fidelity. This technical achievement signifies the viability of Qunnect's quantum networking components to perform entanglement-based protocols over prolonged durations in real-world environments.

Key Points: 
  • Unlike most quantum networks, Qunnect uses atoms at room temperature to generate polarization entangled photons, since these qubits are native to other quantum devices such as sensors and computers.
  • By constructing a stable network to distribute polarization qubits, Qunnect has demonstrated a path forward for other quantum networks to host applications beyond secure communications.
  • For this demonstration, the Qunnect team used its hardware instruments to generate, distribute, and preserve entangled photons over 34 kilometers of fiber within the GothamQ network.
  • By constructing a stable network to distribute polarization qubits, Qunnect has demonstrated a path forward for other quantum networks to host applications beyond secure communications.

Rice Biotech Launch Pad startup Motif Neurotech announces peer-reviewed publication on wireless cortical stimulator for precise neuromodulation

Retrieved on: 
fredag, april 12, 2024

HOUSTON, April 12, 2024 /PRNewswire/ -- Rice University today announced that Jacob Robinson, a professor of electrical and computer engineering and of bioengineering and founder and chief executive officer of Motif Neurotech, a neurotechnology company developing minimally invasive bioelectronics for mental health formed through the Rice Biotech Launch Pad, published a peer-reviewed study in Science Advances detailing a novel and wireless device - an epidural cortical stimulator known as the Digitally programmable Over-brain Therapeutic (DOT), that is capable of receiving enough energy to stimulate human and large-animal brain activity and can deliver bursts of electrical stimulation to the brain through the dura, the tough membrane that covers the brain and the spinal cord. The manuscript entitled "Miniature battery-free epidural cortical stimulators" can be viewed on the Science Advances website.

Key Points: 
  • The manuscript entitled " Miniature battery-free epidural cortical stimulators " can be viewed on the Science Advances website.
  • "However, current neuromodulation devices are either bulky, invasive, or limited in their stimulation capabilities.
  • It overcomes challenges by using a battery-free and wireless approach  to create an implant that can deliver precise and programmable stimulation to the brain, without brain surgery."
  • The study details how the DOT stimulator works by using magnetoelectric antennas that can convert magnetic fields into electric fields and vice versa.

Robert Adamson’s final book is a search for recognition and a poetic tribute to his love of nature

Retrieved on: 
tisdag, april 23, 2024

Birds and Fish: Life on the Hawkesbury – Robert Adamson (Upswell) In 2004, Adamson published Inside Out: An Autobiography.

Key Points: 
  • Birds and Fish: Life on the Hawkesbury – Robert Adamson (Upswell) In 2004, Adamson published Inside Out: An Autobiography.
  • Adamson grew up in Neutral Bay on Sydney’s lower north shore, which afforded him ample opportunity to pursue his interest.
  • It is a terrifying, beautiful scene, recounted not by the fallen boy, of course, but the poet he became.
  • What I think I was aiming for when I stared into each bird’s eyes was some flicker of recognition, some sign of connection between us.
  • What I think I was aiming for when I stared into each bird’s eyes was some flicker of recognition, some sign of connection between us.
  • Theories of recognition have a long history, which in the Western tradition date back at least as far as Hegel.
  • Read more:
    Poetry goes nuclear: 3 recent books delve into present anxieties, finding beauty amid the terror

Blunt and honest

  • This was the year of Mr Roberts, the teacher who introduced me to poetry and what they called nature studies.
  • This was the year of Mr Roberts, the teacher who introduced me to poetry and what they called nature studies.
  • It helped, too, that Mr Roberts “knew a bit about birds” and that he was encouraging about projects and assignments.
  • The young Adamson lights up, a recognition undimmed, even when a new teacher tells him “to forget [his] ambition”.
  • Nature was blunt and honest.
  • There was no third party, no good manners, no god involved – no reasoning or theology, let alone spelling and maths.
  • Nature was blunt and honest.
  • It is to do with the field of being; you can project yourself back to the original lores, rites and rituals.
  • It is to do with the field of being; you can project yourself back to the original lores, rites and rituals.


Craig Billingham has previously received funding from The Australia Council for the Arts (now Create Australia).

EQS-News: HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
onsdag, april 10, 2024

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • "The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans," emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Verana Health to Reveal Results from Largest Pediatric Intraocular Lens Study, Funded by the FDA, During AAPOS 2024

Retrieved on: 
tisdag, april 9, 2024

Verana Health led the analysis utilizing real-world data from the Academy IRIS Registry – one of the largest specialty society clinical data registries in all of medicine.

Key Points: 
  • Verana Health led the analysis utilizing real-world data from the Academy IRIS Registry – one of the largest specialty society clinical data registries in all of medicine.
  • “The results of this study underscore the transformative potential of high-quality, curated real-world data in generating real-world evidence to enhance treatments and improve patients’ lives,” said Sujay Jadhav, CEO of Verana Health.
  • “We thank the FDA for the opportunity to lead this study, and we extend our appreciation to the Academy for its partnership.
  • Verana Health utilized its clinician-directed and artificial intelligence-enhanced population health data engine, VeraQ ®, to analyze curated, de-identified IRIS Registry data on pediatric cataract surgeries, amplifying the depth and accuracy of the study's insights.

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Retrieved on: 
torsdag, april 4, 2024

The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.

Key Points: 
  • The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.
  • The paper describes Sensei Biotherapeutics’ approach to the discovery and development of SNS-101, which was designed to potently and selectively target the active protonated form of VISTA, a protein that plays a significant role in suppressing T-cell activation.
  • SNS-101 is designed to block VISTA by inhibiting its interaction with PSGL-1 on T-cells resulting in T-cell activation.
  • The manuscript published in Nature Communications is entitled “VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response,” and can be found here: https://rdcu.be/dDF8x

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
måndag, april 1, 2024

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Moreover, the neflamapimod treatment effects on GFAP were correlated to clinical outcomes, assessed by the CDR-SB.
  • Cash Position: As of December 31, 2023, CervoMed had $7.8 million in cash and cash equivalents as compared to $4.1 million as of December 31, 2022.
  • This increase was attributed to the RewinD-LB Phase 2b clinical study in DLB which began in the first quarter of 2023.
  • Net Loss: Net Loss was $2.2 million for the year ended December 31, 2023, compared to a net loss of $5.8 million for year ended December 31, 2022.